Navigation Links
CuraGen Announces Top-Line Phase II Results on Velafermin

- Conference call to be hosted today at 8:30 a.m. Eastern Time -

BRANFORD, Conn., Oct. 11 /PRNewswire-FirstCall/ -- CuraGen Corporation (Nasdaq: CRGN), a clinical-stage biopharmaceutical company focused on oncology, announced today that its Phase II dose-confirmatory clinical trial (CLN-12) evaluating a single dose of velafermin for the prevention of severe oral mucositis demonstrated that velafermin was safe and well-tolerated but did not meet its primary endpoint. Based on these results, the Company is discontinuing the development of velafermin, and will continue to focus its resources on belinostat, a Phase II histone deacetylase (HDAC) inhibitor for the treatment of solid tumors and hematologic malignancies, and CR011-vcMMAE, a Phase I/II antibody-drug conjugate for the treatment of metastatic melanoma.

"While we are disappointed that the primary endpoint was not met in this study, on behalf of everyone at CuraGen, I would like to thank all of the patients and investigators who took part in the velafermin development program," commented Timothy Shannon, President and Chief Executive Officer of CuraGen. "We continue to aggressively focus on our goal of advancing the belinostat and CR011-vcMMAE programs toward initiation of Phase III development in 2008, and we look forward to presenting updated clinical trial results on these programs in October at the AACR-NCI-EORTC conference, and in December at the ASH Annual Meeting."

CLN-12 was a randomized, double-blind, placebo-controlled study designed to assess a reduction in the incidence of severe Grade 3 or 4 oral mucositis in patients receiving high-dose chemotherapy followed by autologous bone marrow transplantation (BMT). The trial enrolled 390 patients at 33 centers in the United States. Patients enrolled in the trial were randomized to receive a single infusion of either placebo or one of three dose levels of velafermin (10 mcg/kg, 30 mcg/kg or 60 mcg/kg) administered 24 hours after BMT.

The primary endpoint was a decrease in the incidence of severe oral mucositis in patients receiving 30 mcg/kg velafermin compared to placebo. Secondary endpoints evaluated included duration of oral mucositis, patient self-reported pain score, use of pain medications, the incidence and duration of febrile neutropenia, and use of enteral or parenteral nutrition.

The complete results from CLN-12 will be presented in December at the American Society of Hematology (ASH) 2007 Annual Meeting in Atlanta, GA.

CuraGen will host a conference call today at 8:30 a.m. Eastern Time. Dial-in and webcast information are provided below.

Dial-in and Webcast Information

Date: Thursday, October 11, 2007

Time: 8:30 a.m. EDT

Dial-in: 877-272-5391 (domestic)

706-758-4315 (international)

Passcode: 20509852

Webcast: Access to the live webcast is available at

A replay of the conference call will be available starting at 12:00 p.m. Eastern time on Thursday, October 11, 2007 through Sunday, November 11, 2007 by dialing 800-642-1687 (domestic) or 706-645-9291 (international). The passcode for the replay is 20509852. An archive of the webcast will be available for 30 days at

Pipeline Update

Upcoming Presentations at the AACR-NCI-EORTC 2007 International Conference on Molecular Targets and Cancer Therapeutics, October 22-26, 2007, in San Francisco, CA:


Title: Phase II Multicenter Trial of Belinostat (PXD101) in

Combination with Carboplatin and Paclitaxel (BelCaP) for

Patients (pts) with Relapsed Ovarian Cancer

Date: Thursday, October 25, 2007

Poster Board: C223

Session: Poster Session C: Other Small Molecule Therapeutic Agents

Title: A Phase I Study of Oral Belinostat (PXD101) in Patients

with Advanced Solid Tumors

Date: Wednesday, October 24, 2007

Poster Board: B134

Session: Poster Session B: Epigenetic Targets

Title: A Phase 1 Study of Belinostat (PXD101) in Combination with

Bortezomib in Patients with Advanced Solid Tumors and


Date: Tuesday, October 23, 2007

Poster Board: A149

Session: Poster Session A: Clinical Trials

Title: A Phase II Trial of the Histone Deacetylase Inhibitor

Belinostat (PXD101) in Patients with Platinum Resistant

Epithelial Ovarian Tumors and Micropapillary/Borderline

(LMP) Ovarian Tumors. A Trial of the PMH Phase II


Date: Tuesday, October 23, 2007

Poster Board: A160

Session: Poster Session A: Clinical Trials


Title: A Phase I and Pharmacokinetic Study of CR011-vcMMAE, an

Antibody Toxin Conjugate Drug, in Patients with

Unresectable Stage III /IV Melanoma

Date: Wednesday, October 24, 2007

Poster Board: B47

Session: Poster Session B: Biological Therapeutic Agents

Title: Pharmacologically Enhanced Expression of the

Melanoma-Associated Target, GPNMB, Increases the

Sensitivity of Melanoma Cells to the CR011-vcMMAE

Antibody-Drug Conjugate

Date: Tuesday, October 23, 2007

Poster Board: A68

Session: Poster Session A: Biological Therapeutic Agents

Upcoming Presentations at the 2007 ASH Annual Meeting, December 8-11, 2007 in Atlanta, GA:


Title: Belinostat (PXD101) in Patients with Recurrent or

Refractory Peripheral or Cutaneous T-Cell Lymphoma:

Results of a Phase II Study

Date: Monday, December 10, 2007

Poster Board: 2607

Session: Lymphoma: Chemotherapy, excluding Pre-Clinical Models:

Diffuse Large Cell Lymphoma and T-Cell Lymphoma


Title: A Randomized Placebo Controlled Phase II Trial of

Prevention of Severe Oral Mucositis Using Single Dose

Velafermin in Patients Receiving Myeloablative Therapy and

Autologous Hematopoietic Stem Cell Transplant (AHSCT)

Date: December 10, 2007

Time: 4:00 p.m. Eastern Time

Session: Clinical Care: Transplantation Regimen Toxicities and

Engraftment-Regimen-Related Toxicities

About CuraGen

CuraGen Corporation (Nasdaq: CRGN) is a dedicated clinical-stage biopharmaceutical company developing diverse approaches for the treatment of cancer including belinostat and CR011-vcMMAE. By leveraging the drug development strengths cultivated over the years, CuraGen expects to make a difference by advancing its promising therapeutics to address the unmet medical needs of cancer patients. CuraGen Corporation is headquartered in Branford, Connecticut. For additional information please visit

Safe Harbor

Statements in this press release regarding management's future expectations, beliefs, intentions, goals, strategies, plans or prospects, including statements relating to the advancement of the belinostat and CR011- vcMMAE programs and the projected timing for updates on the CuraGen's clinical trial results may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by terminology such as "anticipate," "believe," "could," "could increase the likelihood," "estimate," "expect," "intend," "is planned," "may," "should," "will," "will enable," "would be expected," "look forward," "may provide," "would" or similar terms, variations of such terms or the negative of those terms. Such forward-looking statements involve known and unknown risks, uncertainties and other factors including the risk that any one or more of CuraGen's drug development programs will not proceed as planned for technical, scientific or commercial reasons or due to patient enrollment issues or based on new information from nonclinical or clinical studies or from other sources, the success of competing products and technologies, CuraGen's stage of development as a biopharmaceutical company, government regulation and healthcare reform, technological uncertainty and product development risks, product liability exposure, uncertainty of additional funding, CuraGen's history of incurring losses and the uncertainty of achieving profitability, reliance on research collaborations and strategic alliances, competition, patent infringement claims against CuraGen's products, processes and technologies, CuraGen's ability to protect its patents and proprietary rights and uncertainties relating to commercialization rights, as well as those risks, uncertainties and factors referred to in the Company's Quarterly Report on Form 10-Q for the quarter ended June 30, 2007, filed with the Securities and Exchange Commission under the section "Risk Factors," as well as other documents that may be filed by CuraGen from time to time with the Securities and Exchange Commission. As a result of such risks, uncertainties and factors, the Company's actual results may differ materially from any future results, performance or achievements discussed in or implied by the forward-looking statements contained herein. CuraGen is providing the information in this press release as of this date and assumes no obligations to update the information included in this press release or revise any forward-looking statements, whether as a result of new information, future events or otherwise.


CuraGen Contact:

Glenn Schulman, Pharm.D.

Director of Investor Relations

(888) 436-6642

SOURCE CuraGen Corporation
Copyright©2007 PR Newswire.
All rights reserved

Related medicine technology :

1. CuraGen Presents Update on Clinical Development Program for Belinostat
2. CuraGen and TopoTarget Announce New Clinical Results With Belinostat to be Reported at Upcoming Major Medical Meetings
3. CuraGen Announces New Preclinical Results with Belinostat and Velafermin to be Presented at AACR Annual Meeting
4. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
5. Sygnis Pharma AG announces date for presentation of clinical results
6. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
8. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
9. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
10. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
11. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
Post Your Comments:
(Date:11/25/2015)... , Nov. 25, 2015  Linden Care, LLC, ... optimizing treatment outcomes for patients suffering from chronic pain, ... for a Temporary Restraining Order (TRO) enjoining Express Scripts ... two companies. --> --> ... all of its legal options. --> ...
(Date:11/25/2015)... AVIV, Israel , November 25, 2015 ... (NASDAQ: KTOV ) (TASE: KTOV), a biopharmaceutical company ... simultaneous treatment of various clinical conditions, today announced the ... 3,158,900 American Depository Shares ( ADSs ), each representing ... purchase up to 3,158,900 ADSs. The ADSs and warrants ...
(Date:11/25/2015)... DUBLIN , Nov. 25, 2015 Endo International ... Rajiv De Silva , President and CEO, will discuss ... Healthcare Conference in New York on ... . Click on Investor Relations, and then the ... prior to the presentation,s start time to visit the site ...
Breaking Medicine Technology:
(Date:11/25/2015)... ... November 25, 2015 , ... Beddit® has launched a new Android app ... new app features a more intuitive SleepScore™ that rates sleep quality on a 100-point ... SleepScore is created by a proprietary algorithm. Beddit analyzes the data to provide an ...
(Date:11/25/2015)... ... November 25, 2015 , ... In an ongoing Clinical ... Center (RMC) in Chicago, IL, UV Angel is evaluating the efficacy of its product ... intensive care units (totaling 30 beds) from May 2014 through October 2015 at a ...
(Date:11/25/2015)... ... , ... Today, Mothers Against Drunk Driving (MADD) learned that the ... the first time since 2011. In 2014, there were 9,967 fatalities involving an alcohol ... National Highway Traffic Safety Administration (NHTSA), 32,675 people were killed in traffic crashes in ...
(Date:11/25/2015)... ... November 25, 2015 , ... In ... nation’s Periwinkle Pioneers, individuals and groups responsible for advancing care for pulmonary hypertension ... Pioneers, nominated by the public, will receive special recognition throughout 2016 as part ...
(Date:11/25/2015)... ... November 25, 2015 , ... Privately owned Contract Development ... expansion of its current state of the art research, development and manufacturing facility ... increase its manufacturing capacity as well as to support its clients’ growing research ...
Breaking Medicine News(10 mins):